Empagliflozin/linagliptin
 | |
 | |
| Combination of | |
|---|---|
| Empagliflozin | SGLT2 inhibitor |
| Linagliptin | DPP-4 inhibitor |
| Clinical data | |
| Trade names | Glyxambi |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C48H55ClN8O9 |
| Molar mass | 923.47 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Empagliflozin/linagliptin, sold under the brand name Glyxambi, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes.[5][6] It is a combination of empagliflozin and linagliptin.[5][6] It is taken by mouth.[5][6]
The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections .[5][6]
It was approved for use in the United States in January 2015,[7][8] for use in the European Union in November 2016,[6] and for use in Australia in December 2016.[2]
Medical uses
[edit]In the United States empagliflozin/linagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.[5]
In the European Union empagliflozin/linagliptin is indicated in adults aged 18 years and older with type 2 diabetes mellitus:[6]
- to improve glycemic control when metformin and/or sulphonylurea (SU) and empagliflozin or linagliptin do not provide adequate glycemic control;[6]
- when already being treated with the free combination of empagliflozin and linagliptin.[6]
Adverse effects
[edit]The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections .[5][6] The most serious side effects include ketoacidosis (high blood levels of acids called ‘ketoacids’), pancreatitis (inflammation of the pancreas), hypersensitivity (allergic reactions) and hypoglycaemia (low blood sugar levels).[6]
History
[edit]The combination preparation was developed and is marketed by Boehringer Ingelheim and Eli Lilly and Company under the brand name Glyxambi.[9]
References
[edit]- ^ "Empagliflozin / linagliptin (Glyxambi) Use During Pregnancy". Drugs.com. 29 November 2018. Retrieved 10 February 2020.
- ^ a b "Summary for ARTG Entry: 263557 Glyxambi 25 mg/5 mg empagliflozin/linagliptin 25mg/5mg film coated tablet blister pack". Therapeutic Goods Administration (TGA).
- ^ "Glyxambi 10 mg/5 mg Film-coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 18 December 2019. Retrieved 10 February 2020.
- ^ "Glyxambi 25 mg/5 mg Film-coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 18 December 2019. Retrieved 10 February 2020.
- ^ a b c d e f g "Glyxambi- empagliflozin and linagliptin tablet, film coated". DailyMed. 22 January 2020. Retrieved 3 April 2020.
- ^ a b c d e f g h i j k "Glyxambi EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 3 April 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Glyxambi (empagliflozin and linagliptin) tablets". U.S. Food and Drug Administration (FDA). 11 April 2016. Retrieved 10 February 2020.
- ^ "Glyxambi: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 10 February 2020.
- ^ Raedler LA (March 2015). "Glyxambi (Empagliflozin/Linagliptin): A Dual-Acting Oral Medication Approved for the Treatment of Patients with Type 2 Diabetes". Am Health Drug Benefits. 8 (Spec Feature): 171–5. PMC 4665058. PMID 26629285.
